Payment overview · 2025
General Payments
$264.54
15 reported records · 8 companies
Healthcare provider profile · identity verified
Douglas Harold Desantis, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HAVELOCK, NC · NPI 1275509705
Verified facts
What the public records show
CMS Open Payments records show Douglas Harold Desantis, MD received $264.54 in general payments during 2025 across 15 reported records.
Amgen Inc. accounted for 25.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $67.49 | 25.5% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $50.15 | 19.0% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $46.26 | 17.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $27.64 | 10.4% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.68 | 8.6% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $19.37 | 7.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.18 | 6.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.77 | 5.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $264.54 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $67.49 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $50.15 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $50.15 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $46.26 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $22.68 | 1 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $19.37 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.18 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.77 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.77 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.46 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.14 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 40 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 45 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 104 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
45 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
48 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
104 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
40 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 278 | 74 |
| Amlodipine Besylate | Amlodipine Besylate | 266 | 75 |
| Levothyroxine Sodium | Levothyroxine Sodium | 248 | 57 |
| Omeprazole | Omeprazole | 186 | 51 |
| Tramadol Hcl | Tramadol Hcl | 171 | 48 |
| Prednisone | Prednisone | 166 | 90 |
| Metoprolol Succinate | Metoprolol Succinate | 160 | 51 |
| Gabapentin | Gabapentin | 155 | 37 |
| Glimepiride | Glimepiride | 146 | 34 |
| Lisinopril | Lisinopril | 139 | 39 |
| Furosemide | Furosemide | 137 | 35 |
| Montelukast Sodium | Montelukast Sodium | 130 | 39 |
| Lorazepam | Lorazepam | 128 | 35 |
| Celecoxib | Celecoxib | 125 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 116 | 31 |
| Losartan Potassium | Losartan Potassium | 114 | 34 |
| Simvastatin | Simvastatin | 110 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 109 | 20 |
| Ozempic | Semaglutide | 104 | 19 |
| Metformin Hcl | Metformin Hcl | 101 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 96 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 93 | 18 |
| Allopurinol | Allopurinol | 91 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 89 | 28 |
| Trazodone Hcl | Trazodone Hcl | 89 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 88 | 21 |
| Alprazolam | Alprazolam | 86 | 22 |
| Metformin Hcl Er | Metformin Hcl | 84 | 25 |
| Sertraline Hcl | Sertraline Hcl | 81 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 79 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 75 | 27 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 74 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 71 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 70 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 68 | 15 |
| Azithromycin | Azithromycin | 66 | 48 |
| Clonazepam | Clonazepam | 66 | 12 |
| Atenolol | Atenolol | 65 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 65 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 63 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 63 | 16 |
| Meloxicam | Meloxicam | 61 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 60 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 59 | 15 |
| Clonidine Hcl | Clonidine Hcl | 56 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 49 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 49 | 17 |
| Famotidine | Famotidine | 49 | 15 |
| Warfarin Sodium | Warfarin Sodium | 49 | suppressed |
| Temazepam | Temazepam | 48 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 48 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 27 |
| Carvedilol | Carvedilol | 47 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 47 | 36 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 47 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 47 | suppressed |
| Torsemide | Torsemide | 47 | 13 |
| Diazepam | Diazepam | 45 | 11 |
| Donepezil Hcl | Donepezil Hcl | 45 | suppressed |
| Jardiance | Empagliflozin | 45 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 44 | 12 |
| Bupropion Xl | Bupropion Hcl | 43 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 43 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 43 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 42 | 12 |
| Potassium Chloride | Potassium Chloride | 42 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | 11 |
| Alendronate Sodium | Alendronate Sodium | 40 | 13 |
| Cefuroxime | Cefuroxime Axetil | 40 | 32 |
| Eliquis | Apixaban | 40 | 13 |
| Amoxicillin | Amoxicillin | 38 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 37 | 11 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 36 | 28 |
| Ondansetron Odt | Ondansetron | 36 | 15 |
| Ketoconazole | Ketoconazole | 34 | 18 |
| Spironolactone | Spironolactone | 33 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Fluconazole | Fluconazole | 29 | 11 |
| Linzess | Linaclotide | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 26 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 11 |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 15 |
| Doxepin Hcl | Doxepin Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 21 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 14 |
| Glipizide Er | Glipizide | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Pro Comfort Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Clarithromycin | Clarithromycin | 11 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $264.54 · 15 records | Amgen Inc. | AREXVY, Bimzelx, ELIQUIS, JARDIANCE, Kerendia, NURTEC ODT, OTEZLA, Ozempic, REPATHA, Rybelsus, SHINGRIX, VOQUEZNA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error